(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Which Carrier Do You Suggest? Vote - 2The hunt for dark matter: a trivia quiz
- 3The Main 15 Applications for Efficiency and Association
- 4Study reveals links between global food systems, obesity, and climate change
- 5Shredded cheese recall: Multiple brands sold at Aldi, Target and Walmart affected over potential metal fragment contamination
- 7 Odd Apparatuses to Make Your Party Stick Out!
- 7 Fast Approaches to Let loose Space on Your Telephone in a flash
- 'All's Fair,' Ryan Murphy's new show starring Kim Kardashian, hit with scathing reviews: 'A girlboss fever dream'
- Figure out How to Pick the Right Dental specialist for Your Dental Inserts
- Carina Nebula shines with white-blue stars | Space photo of the day for Jan. 5, 2026
- Top 20 Wellbeing and Wellness Applications for a Sound Way of life
- 6 Natural products High In Vitamins,Which One Do You Like to Eat
- How grandchildren are stepping up to fill the caregiver gap
- The Best Games On the planet
